Earnings Call Summary | Singular Genomics(OMIC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Singular Genomics(OMIC.US) Q1 2024 Earnings Conference
The following is a summary of the Singular Genomics Systems, Inc. (OMIC) Q1 2024 Earnings Call Transcript:
以下是奇異基因組系統公司（OMIC）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Singular Genomics Systems, Inc. reported a Q1 revenue of approximately $0.4 million.
The company experienced a negative gross margin due to initial discounts on capital purchases coupled with higher system placement costs.
Operating expenses rose to $26.4 million from the previous year's $25.4 million.
The net loss was $25 million or $0.34 per share, a mild increase compared to $23.6 million, or $0.33 per share, in Q1 2023.
The company holds cash, cash equivalents, and short-term investments totaling $150.7 million.
Singular Genomics Systems, Inc.報告稱，第一季度收入約爲40萬美元。
由於資本購買的初始折扣以及更高的系統投放成本，該公司的毛利率爲負。
運營支出從上一年的2540萬美元增至2640萬美元。
淨虧損爲2500萬美元，合每股虧損0.34美元，與2023年第一季度的2360萬美元或每股虧損0.33美元相比略有增加。
該公司持有總額爲1.507億美元的現金、現金等價物和短期投資。
Business Progress:
業務進展：
During the quarter, Singular Genomics shipped six G4 instruments, increasing the total to 30 as of March 31.
The company is actively developing the G4X platform and spatial sequencing methods and is preparing for the launch of the G4X Spatial Sequencer.
Singular Genomics has announced the launch of G4X Technology Access Services program in Q2, with service projects expected to increase in H2 2024.
The company has advanced collaboration with research institutions such as Dana Farber Cancer Institute and Broad Institute highlighting the potential of G4X in translational research.
Expansion of the company's commercial panel from a 150-gene to 300-gene panel is anticipated by the end of the current quarter.
Many projects are in pipeline which are expected to result in academic publications, thus increasing the company's visibility.
Singular Genomics is utilizing the speed advantage of its G4 chemistry, developed over the last five years, in combination with an innovative instrument design to deliver unique spatial results.
On the legal front, several patents related to the use of sequencing as a modality in spatial orientation have been filed.
在本季度，Singular Genomics出貨了六臺G4儀器，截至3月31日，總數增加到30臺。
該公司正在積極開發G4X平台和空間測序方法，並正在爲G4X空間測序器的推出做準備。
Singular Genomics宣佈在第二季度啓動G4X技術訪問服務計劃，服務項目預計將在2024年下半年增加。
該公司與達納·法伯癌症研究所和布羅德研究所等研究機構加強了合作，突顯了G4X在轉化研究中的潛力。
預計到本季度末，該公司的商業樣本將從150基因組擴大到300基因。
許多項目正在籌備中，預計將發表學術出版物，從而提高公司的知名度。
Singular Genomics正在利用其在過去五年中開發的G4化學的速度優勢，與創新的儀器設計相結合，以提供獨特的空間結果。
在法律方面，已經申請了幾項與使用測序作爲空間定向模式相關的專利。
More details: Singular Genomics IR
更多詳情： 奇異基因組學 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。